Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PITAC in malignant pleural effusion (MaPEPi)
2024-511255-17-00Phase 2Withdrawn
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Dec 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin and doxorubicin in pleural carcinomatosis and malignant pleural effusion (MPE), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoint: PITAC efficacy on pleurodesis and control of malignant pleural effusion volume. Planned start Dec 2025; status: withdrawn.
02
Drugs
cisplatindoxorubicin
03
Conditions
pleural carcinomatosismalignant pleural effusion (MPE)
Beyond the preview
Go deeper on 2024-511255-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511255-17-00.